周五盘中，勒梅特微管医疗（LMAT）股价大跌5.14%，主要原因是公司公布的季度财报未能达到分析师预期。
根据最新财报，截至3月31日的季度，勒梅特微管医疗调整后每股收益为0.48美元，低于分析师平均预期的0.50美元。尽管公司收入同比增长12%达到5987万美元，超过了预期的5764万美元，但盈利未达预期仍然引发了投资者的担忧。
值得注意的是，尽管本季度业绩未达预期，勒梅特微管医疗的股价在过去一个季度仍上涨了8.2%。然而，年初至今该股已下跌1.5%。分析师仍然对该公司保持乐观态度，目前对该股的平均评级为"买入"，12个月目标价中位数为108.00美元。这次财报可能会影响分析师对公司未来表现的预期，投资者应密切关注后续的分析师评级变化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.